DOI: 10.1038/sj.gt.3302579. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity

Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity

10.1038/sj.gt.3302579

Crossref journal-article

Springer Science and Business Media LLC

Gene Therapy (297)

Bibliography

Marano, R. J., Toth, I., Wimmer, N., Brankov, M., & Rakoczy, P. E. (2005). Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Therapy, 12(21), 1544â1550.

Authors 5

R J Marano (first)
I Toth (additional)
N Wimmer (additional)
M Brankov (additional)
P E Rakoczy (additional)

References 27 Referenced 135

Ohno-Matsui K et al. Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 2001; 189: 323–333. (10.1002/jcp.10026) / J Cell Physiol by K Ohno-Matsui (2001)
Aiello LP et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480–1487. (10.1056/NEJM199412013312203) / N Engl J Med by LP Aiello (1994)
Boulton M, Foreman D, Williams G, McLeod D . VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998; 82: 561–568. (10.1136/bjo.82.5.561) / Br J Ophthalmol by M Boulton (1998)
Siemeister G, Martiny-Baron G, Marme D . The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Cancer Metast Rev 1998; 17: 241–248. (10.1023/A:1006027124696) / Cancer Metast Rev by G Siemeister (1998)
Bainbridge JW et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Therapy 2002; 9: 320–326. (10.1038/sj.gt.3301680) / Gene Therapy by JW Bainbridge (2002)
Lai YK et al. Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Therapy 2002; 9: 804–813. (10.1038/sj.gt.3301695) / Gene Therapy by YK Lai (2002)
Carrasquillo KG et al. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci 2003; 44: 290–299. (10.1167/iovs.01-1156) / Invest Ophthalmol Vis Sci by KG Carrasquillo (2003)
Alama A, Barbieri F, Cagnoli M, Schettini G . Antisense oligonucleotides as therapeutic agents. Pharmacol Res 1997; 36: 171–178. (10.1006/phrs.1997.0227) / Pharmacol Res by A Alama (1997)
Rojanasakul Y . Antisense oligonucleotide therapeutics: drug delivery and targeting. Adv Drug Deliv Rev 1996; 18: 115–131. (10.1016/0169-409X(95)00020-8) / Adv Drug Deliv Rev by Y Rojanasakul (1996)
Urban E, Noe CR . Structural modifications of antisense oligonucleotides. Farmaco 2003; 58: 243–258. (10.1016/S0014-827X(03)00022-3) / Farmaco by E Urban (2003)
Garrett KL, Shen WY, Rakoczy PE . In vivo use of oligonucleotides to inhibit choroidal neovascularisation in the eye. J Gene Med 2001; 3: 373–383. (10.1002/jgm.197) / J Gene Med by KL Garrett (2001)
Marano RJ et al. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp Eye Res 2004; 79: 525–535. (10.1016/j.exer.2004.06.023) / Exp Eye Res by RJ Marano (2004)
Wimmer N et al. Syntheses of polycationic dendrimers on lipophilic peptide core for complexation and transport of oligonucleotides. Bioorg Med Chem Lett 2002; 12: 2635–2637. (10.1016/S0960-894X(02)00511-5) / Bioorg Med Chem Lett by N Wimmer (2002)
Marano RJ, Rakoczy PE . Treatments for choroidal and retinal neovascularisation of the retina: a focus on oligonucleotide therapy and their delivery, for the regulation of gene function. Clin Exp Ophthalmol 2005; 33: 81–89. (10.1111/j.1442-9071.2005.00952.x) / Clin Exp Ophthalmol by RJ Marano (2005)
Group TES . Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003; 110: 979–986. (10.1016/S0161-6420(03)00085-X) / Ophthalmology by TES Group (2003)
Tolentino MJ et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 2004; 24: 132–138. (10.1097/00006982-200402000-00018) / Retina by MJ Tolentino (2004)
Shen WY et al. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat. Br J Ophthalmol 1998; 82: 1063–1071. (10.1136/bjo.82.9.1063) / Br J Ophthalmol by WY Shen (1998)
Stephens AC, Rivers RP . Antisense oligonucleotide therapy in cancer. Curr Opin Mol Ther 2003; 5: 118–122. / Curr Opin Mol Ther by AC Stephens (2003)
Stein CA, Cheng YC . Antisense oligonucleotides as therapeutic agents – is the bullet really magical? Science 1993; 261: 1004–1012. (10.1126/science.8351515) / Science by CA Stein (1993)
Bell C et al. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In vitro Cell Dev Biol Anim 1999; 35: 533–542. (10.1007/s11626-999-0064-y) / In vitro Cell Dev Biol Anim by C Bell (1999)
Group TES . Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002; 22: 143–152. (10.1097/00006982-200204000-00002) / Retina by TES Group (2002)
Axel DI et al. Toxicity, uptake kinetics and efficacy of new transfection reagents: increase of oligonucleotide uptake. J Vasc Res 2000; 37: 221–234; discussion 303–304.. (10.1159/000025737) / J Vasc Res by DI Axel (2000)
Neerman MF, Zhang W, Parrish AR, Simanek EE . In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery. Int J Pharm 2004; 281: 129–132. (10.1016/j.ijpharm.2004.04.023) / Int J Pharm by MF Neerman (2004)
Shah DS et al. DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers. Int J Pharm 2000; 208: 41–48. (10.1016/S0378-5173(00)00534-2) / Int J Pharm by DS Shah (2000)
Marano RJ, Rakoczy EP . Use of densitometry for evaluating severity of laser photocoagulation induced CNV: an improved method. Biotech and Histochem 2005 (in press).
Lambert V et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J 2001; 15: 1021–1027. (10.1096/fj.00-0393com) / FASEB J by V Lambert (2001)
Schols P, Smets E . Carnoy: analysis software for LM, SEM and TEM images. 2001, Leuven: distributed by the authors, http://www.carnoy.org.

Dates

Type	When
Created	20 years, 1 month ago (July 21, 2005, 5:48 a.m.)
Deposited	3 years, 4 months ago (March 30, 2022, 12:06 a.m.)
Indexed	1 month ago (July 24, 2025, 7:24 a.m.)
Issued	20 years, 1 month ago (June 30, 2005)
Published	20 years, 1 month ago (June 30, 2005)
Published Online	20 years, 1 month ago (June 30, 2005)
Published Print	19 years, 9 months ago (Nov. 1, 2005)

Funders 0

None

BibTeX

@article{Marano_2005, title={Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity}, volume={12}, ISSN={1476-5462}, url={http://dx.doi.org/10.1038/sj.gt.3302579}, DOI={10.1038/sj.gt.3302579}, number={21}, journal={Gene Therapy}, publisher={Springer Science and Business Media LLC}, author={Marano, R J and Toth, I and Wimmer, N and Brankov, M and Rakoczy, P E}, year={2005}, month=jun, pages={1544–1550} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2025,
        7,
        24
      ]
    ],
    "date-time": "2025-07-24T11:24:49Z",
    "timestamp": 1753356289283
  },
  "reference-count": 27,
  "publisher": "Springer Science and Business Media LLC",
  "issue": "21",
  "license": [
    {
      "start": {
        "date-parts": [
          [
            2005,
            6,
            30
          ]
        ],
        "date-time": "2005-06-30T00:00:00Z",
        "timestamp": 1120089600000
      },
      "content-version": "tdm",
      "delay-in-days": 0,
      "URL": "https://www.springer.com/tdm"
    },
    {
      "start": {
        "date-parts": [
          [
            2005,
            6,
            30
          ]
        ],
        "date-time": "2005-06-30T00:00:00Z",
        "timestamp": 1120089600000
      },
      "content-version": "vor",
      "delay-in-days": 0,
      "URL": "https://www.springer.com/tdm"
    }
  ],
  "content-domain": {
    "domain": [
      "link.springer.com"
    ],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2005,
        11
      ]
    ]
  },
  "DOI": "10.1038/sj.gt.3302579",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2005,
        7,
        21
      ]
    ],
    "date-time": "2005-07-21T09:48:31Z",
    "timestamp": 1121939311000
  },
  "page": "1544-1550",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "source": "Crossref",
  "is-referenced-by-count": 135,
  "title": "Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity",
  "prefix": "10.1038",
  "volume": "12",
  "author": [
    {
      "given": "R J",
      "family": "Marano",
      "sequence": "first",
      "affiliation": []
    },
    {
      "given": "I",
      "family": "Toth",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "N",
      "family": "Wimmer",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "M",
      "family": "Brankov",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "P E",
      "family": "Rakoczy",
      "sequence": "additional",
      "affiliation": []
    }
  ],
  "member": "297",
  "published-online": {
    "date-parts": [
      [
        2005,
        6,
        30
      ]
    ]
  },
  "reference": [
    {
      "key": "BF3302579_CR1",
      "doi-asserted-by": "publisher",
      "first-page": "323",
      "DOI": "10.1002/jcp.10026",
      "volume": "189",
      "author": "K Ohno-Matsui",
      "year": "2001",
      "unstructured": "Ohno-Matsui K et al. Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 2001; 189: 323\u2013333.",
      "journal-title": "J Cell Physiol"
    },
    {
      "key": "BF3302579_CR2",
      "doi-asserted-by": "publisher",
      "first-page": "1480",
      "DOI": "10.1056/NEJM199412013312203",
      "volume": "331",
      "author": "LP Aiello",
      "year": "1994",
      "unstructured": "Aiello LP et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480\u20131487.",
      "journal-title": "N Engl J Med"
    },
    {
      "key": "BF3302579_CR3",
      "doi-asserted-by": "publisher",
      "first-page": "561",
      "DOI": "10.1136/bjo.82.5.561",
      "volume": "82",
      "author": "M Boulton",
      "year": "1998",
      "unstructured": "Boulton M, Foreman D, Williams G, McLeod D . VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998; 82: 561\u2013568.",
      "journal-title": "Br J Ophthalmol"
    },
    {
      "key": "BF3302579_CR4",
      "doi-asserted-by": "publisher",
      "first-page": "241",
      "DOI": "10.1023/A:1006027124696",
      "volume": "17",
      "author": "G Siemeister",
      "year": "1998",
      "unstructured": "Siemeister G, Martiny-Baron G, Marme D . The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Cancer Metast Rev 1998; 17: 241\u2013248.",
      "journal-title": "Cancer Metast Rev"
    },
    {
      "key": "BF3302579_CR5",
      "doi-asserted-by": "publisher",
      "first-page": "320",
      "DOI": "10.1038/sj.gt.3301680",
      "volume": "9",
      "author": "JW Bainbridge",
      "year": "2002",
      "unstructured": "Bainbridge JW et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Therapy 2002; 9: 320\u2013326.",
      "journal-title": "Gene Therapy"
    },
    {
      "key": "BF3302579_CR6",
      "doi-asserted-by": "publisher",
      "first-page": "804",
      "DOI": "10.1038/sj.gt.3301695",
      "volume": "9",
      "author": "YK Lai",
      "year": "2002",
      "unstructured": "Lai YK et al. Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Therapy 2002; 9: 804\u2013813.",
      "journal-title": "Gene Therapy"
    },
    {
      "key": "BF3302579_CR7",
      "doi-asserted-by": "publisher",
      "first-page": "290",
      "DOI": "10.1167/iovs.01-1156",
      "volume": "44",
      "author": "KG Carrasquillo",
      "year": "2003",
      "unstructured": "Carrasquillo KG et al. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci 2003; 44: 290\u2013299.",
      "journal-title": "Invest Ophthalmol Vis Sci"
    },
    {
      "key": "BF3302579_CR8",
      "doi-asserted-by": "publisher",
      "first-page": "171",
      "DOI": "10.1006/phrs.1997.0227",
      "volume": "36",
      "author": "A Alama",
      "year": "1997",
      "unstructured": "Alama A, Barbieri F, Cagnoli M, Schettini G . Antisense oligonucleotides as therapeutic agents. Pharmacol Res 1997; 36: 171\u2013178.",
      "journal-title": "Pharmacol Res"
    },
    {
      "key": "BF3302579_CR9",
      "doi-asserted-by": "publisher",
      "first-page": "115",
      "DOI": "10.1016/0169-409X(95)00020-8",
      "volume": "18",
      "author": "Y Rojanasakul",
      "year": "1996",
      "unstructured": "Rojanasakul Y . Antisense oligonucleotide therapeutics: drug delivery and targeting. Adv Drug Deliv Rev 1996; 18: 115\u2013131.",
      "journal-title": "Adv Drug Deliv Rev"
    },
    {
      "key": "BF3302579_CR10",
      "doi-asserted-by": "publisher",
      "first-page": "243",
      "DOI": "10.1016/S0014-827X(03)00022-3",
      "volume": "58",
      "author": "E Urban",
      "year": "2003",
      "unstructured": "Urban E, Noe CR . Structural modifications of antisense oligonucleotides. Farmaco 2003; 58: 243\u2013258.",
      "journal-title": "Farmaco"
    },
    {
      "key": "BF3302579_CR11",
      "doi-asserted-by": "publisher",
      "first-page": "373",
      "DOI": "10.1002/jgm.197",
      "volume": "3",
      "author": "KL Garrett",
      "year": "2001",
      "unstructured": "Garrett KL, Shen WY, Rakoczy PE . In vivo use of oligonucleotides to inhibit choroidal neovascularisation in the eye. J Gene Med 2001; 3: 373\u2013383.",
      "journal-title": "J Gene Med"
    },
    {
      "key": "BF3302579_CR12",
      "doi-asserted-by": "publisher",
      "first-page": "525",
      "DOI": "10.1016/j.exer.2004.06.023",
      "volume": "79",
      "author": "RJ Marano",
      "year": "2004",
      "unstructured": "Marano RJ et al. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp Eye Res 2004; 79: 525\u2013535.",
      "journal-title": "Exp Eye Res"
    },
    {
      "key": "BF3302579_CR13",
      "doi-asserted-by": "publisher",
      "first-page": "2635",
      "DOI": "10.1016/S0960-894X(02)00511-5",
      "volume": "12",
      "author": "N Wimmer",
      "year": "2002",
      "unstructured": "Wimmer N et al. Syntheses of polycationic dendrimers on lipophilic peptide core for complexation and transport of oligonucleotides. Bioorg Med Chem Lett 2002; 12: 2635\u20132637.",
      "journal-title": "Bioorg Med Chem Lett"
    },
    {
      "key": "BF3302579_CR14",
      "doi-asserted-by": "publisher",
      "first-page": "81",
      "DOI": "10.1111/j.1442-9071.2005.00952.x",
      "volume": "33",
      "author": "RJ Marano",
      "year": "2005",
      "unstructured": "Marano RJ, Rakoczy PE . Treatments for choroidal and retinal neovascularisation of the retina: a focus on oligonucleotide therapy and their delivery, for the regulation of gene function. Clin Exp Ophthalmol 2005; 33: 81\u201389.",
      "journal-title": "Clin Exp Ophthalmol"
    },
    {
      "key": "BF3302579_CR15",
      "doi-asserted-by": "publisher",
      "first-page": "979",
      "DOI": "10.1016/S0161-6420(03)00085-X",
      "volume": "110",
      "author": "TES Group",
      "year": "2003",
      "unstructured": "Group TES . Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003; 110: 979\u2013986.",
      "journal-title": "Ophthalmology"
    },
    {
      "key": "BF3302579_CR16",
      "doi-asserted-by": "publisher",
      "first-page": "132",
      "DOI": "10.1097/00006982-200402000-00018",
      "volume": "24",
      "author": "MJ Tolentino",
      "year": "2004",
      "unstructured": "Tolentino MJ et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 2004; 24: 132\u2013138.",
      "journal-title": "Retina"
    },
    {
      "key": "BF3302579_CR17",
      "doi-asserted-by": "publisher",
      "first-page": "1063",
      "DOI": "10.1136/bjo.82.9.1063",
      "volume": "82",
      "author": "WY Shen",
      "year": "1998",
      "unstructured": "Shen WY et al. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat. Br J Ophthalmol 1998; 82: 1063\u20131071.",
      "journal-title": "Br J Ophthalmol"
    },
    {
      "key": "BF3302579_CR18",
      "first-page": "118",
      "volume": "5",
      "author": "AC Stephens",
      "year": "2003",
      "unstructured": "Stephens AC, Rivers RP . Antisense oligonucleotide therapy in cancer. Curr Opin Mol Ther 2003; 5: 118\u2013122.",
      "journal-title": "Curr Opin Mol Ther"
    },
    {
      "key": "BF3302579_CR19",
      "doi-asserted-by": "publisher",
      "first-page": "1004",
      "DOI": "10.1126/science.8351515",
      "volume": "261",
      "author": "CA Stein",
      "year": "1993",
      "unstructured": "Stein CA, Cheng YC . Antisense oligonucleotides as therapeutic agents \u2013 is the bullet really magical? Science 1993; 261: 1004\u20131012.",
      "journal-title": "Science"
    },
    {
      "key": "BF3302579_CR20",
      "doi-asserted-by": "publisher",
      "first-page": "533",
      "DOI": "10.1007/s11626-999-0064-y",
      "volume": "35",
      "author": "C Bell",
      "year": "1999",
      "unstructured": "Bell C et al. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In vitro Cell Dev Biol Anim 1999; 35: 533\u2013542.",
      "journal-title": "In vitro Cell Dev Biol Anim"
    },
    {
      "key": "BF3302579_CR21",
      "doi-asserted-by": "publisher",
      "first-page": "143",
      "DOI": "10.1097/00006982-200204000-00002",
      "volume": "22",
      "author": "TES Group",
      "year": "2002",
      "unstructured": "Group TES . Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002; 22: 143\u2013152.",
      "journal-title": "Retina"
    },
    {
      "key": "BF3302579_CR22",
      "doi-asserted-by": "publisher",
      "first-page": "221",
      "DOI": "10.1159/000025737",
      "volume": "37",
      "author": "DI Axel",
      "year": "2000",
      "unstructured": "Axel DI et al. Toxicity, uptake kinetics and efficacy of new transfection reagents: increase of oligonucleotide uptake. J Vasc Res 2000; 37: 221\u2013234; discussion 303\u2013304..",
      "journal-title": "J Vasc Res"
    },
    {
      "key": "BF3302579_CR23",
      "doi-asserted-by": "publisher",
      "first-page": "129",
      "DOI": "10.1016/j.ijpharm.2004.04.023",
      "volume": "281",
      "author": "MF Neerman",
      "year": "2004",
      "unstructured": "Neerman MF, Zhang W, Parrish AR, Simanek EE . In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery. Int J Pharm 2004; 281: 129\u2013132.",
      "journal-title": "Int J Pharm"
    },
    {
      "key": "BF3302579_CR24",
      "doi-asserted-by": "publisher",
      "first-page": "41",
      "DOI": "10.1016/S0378-5173(00)00534-2",
      "volume": "208",
      "author": "DS Shah",
      "year": "2000",
      "unstructured": "Shah DS et al. DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers. Int J Pharm 2000; 208: 41\u201348.",
      "journal-title": "Int J Pharm"
    },
    {
      "key": "BF3302579_CR25",
      "unstructured": "Marano RJ, Rakoczy EP . Use of densitometry for evaluating severity of laser photocoagulation induced CNV: an improved method. Biotech and Histochem 2005 (in press)."
    },
    {
      "key": "BF3302579_CR26",
      "doi-asserted-by": "publisher",
      "first-page": "1021",
      "DOI": "10.1096/fj.00-0393com",
      "volume": "15",
      "author": "V Lambert",
      "year": "2001",
      "unstructured": "Lambert V et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J 2001; 15: 1021\u20131027.",
      "journal-title": "FASEB J"
    },
    {
      "key": "BF3302579_CR27",
      "unstructured": "Schols P, Smets E . Carnoy: analysis software for LM, SEM and TEM images. 2001, Leuven: distributed by the authors, http://www.carnoy.org."
    }
  ],
  "container-title": "Gene Therapy",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://www.nature.com/articles/3302579.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/3302579",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/3302579.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2022,
        3,
        30
      ]
    ],
    "date-time": "2022-03-30T04:06:39Z",
    "timestamp": 1648613199000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/3302579"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2005,
        6,
        30
      ]
    ]
  },
  "references-count": 27,
  "journal-issue": {
    "issue": "21",
    "published-print": {
      "date-parts": [
        [
          2005,
          11
        ]
      ]
    }
  },
  "alternative-id": [
    "BF3302579"
  ],
  "URL": "http://dx.doi.org/10.1038/sj.gt.3302579",
  "relation": {},
  "ISSN": [
    "0969-7128",
    "1476-5462"
  ],
  "subject": [],
  "container-title-short": "Gene Ther",
  "published": {
    "date-parts": [
      [
        2005,
        6,
        30
      ]
    ]
  },
  "assertion": [
    {
      "value": "10 December 2004",
      "order": 1,
      "name": "received",
      "label": "Received",
      "group": {
        "name": "ArticleHistory",
        "label": "Article History"
      }
    },
    {
      "value": "12 May 2005",
      "order": 2,
      "name": "accepted",
      "label": "Accepted",
      "group": {
        "name": "ArticleHistory",
        "label": "Article History"
      }
    },
    {
      "value": "30 June 2005",
      "order": 3,
      "name": "first_online",
      "label": "First Online",
      "group": {
        "name": "ArticleHistory",
        "label": "Article History"
      }
    }
  ]
}